Abstract
This study investigates the utility of Hydrogen 1 (1H) magnetic resonance spectroscopy as a noninvasive test for steatosis of response to interferon and ribavirin treatment in patients developing different severity of hepatitis C virus (HCV). Ninety chronic hepatitis C patients undergoing antiviral therapy with interferon and ribavirin underwent 1H MR spectroscopy at 3.0T before treatment, 6 month after the start of treatment and one year after the start of treatment. Peak value of lipid, area under the peak of lipid, peak ratio of lipid, water and area ratio under the peak of lipid, water statistical difference between baseline of control group and antiviral group, and also between baseline and after the start of therapy 6 month of antiviral therapy group. 1H MRS is a noninvasive technique that can be used to provide liver steatosis information on hepatic metabolic processes. This study indicates that the 1H MRS can be used as an indicator of steatosis response to antiviral treatment in chronic hepatitis C patients. Key words: Hydrogen 1 (1H), magnetic resonance spectroscopy (MRS), hepatitis C, antiviral therapy.
Highlights
For the reason of obesity and insulin resistance in nonalcoholic fatty liver disease (NAFLD), the prevalence of hepatic steatosis is increasing rapidly in the world (Angulo, 2002; Williams, 2006)
In NAFLD, steatosis is the hepatic manifestation of the metabolic syndrome and the earliest biomarker for the development of liver fibrosis in the more severe condition of non-alcoholic steatohepatitis (NASH)
Baseline Child-Pugh scores, total bilirubin, and hepatic encephalopathy were not different between the two groups, significant differences in serum albumin, international normalized ratio (INR) for prothrombin time, and ascites were observed between the treatment and control groups (p = 0.002, p = 0.018, and p < 0.001, respectively)
Summary
For the reason of obesity and insulin resistance in nonalcoholic fatty liver disease (NAFLD), the prevalence of hepatic steatosis is increasing rapidly in the world (Angulo, 2002; Williams, 2006). Simple nonalcoholic steatosis can progress to more serious liver disease (nonalcoholic steatohepatitis and cirrhosis), representing a threat to public health. Diagnosis and quantification of hepatic steatosis is important. In NAFLD, steatosis is the hepatic manifestation of the metabolic syndrome and the earliest biomarker for the development of liver fibrosis in the more severe condition of non-alcoholic steatohepatitis (NASH). Diagnosis and treatment of NASH can prevent the potential development of cirrhosis and hepatocellular carcinoma (HCC) (Adams et al, 2005; Farrell and Larter, 2006; Rector et al, 2008).
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
